Therapeutic potential of prostaglandin analogues in glaucoma

Expert Opinion on Investigational Drugs

Volumn 10, Issue 4, 2001, Pages 679-694

  Linden C ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Glaucoma; IOP; Latanoprost; Prostaglandin analogue; Unoprostone

Indexed keywords

ACETAZOLAMIDE; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; ARACHIDONIC ACID; AUTACOID; BENZALKONIUM CHLORIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIAMOX DEPOT; DICLOFENAC; DIPIVEFRINE; DORZOLAMIDE; FLUOROMETHOLONE; LATANOPROST; PHYSOSTIGMINE; PILOCARPINE; PLACEBO; PRODRUG; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN F2 ALPHA ISOPROPYL ESTER; TIMOLOL; TRAVOPOST; UF 201; UNCLASSIFIED DRUG; UNOPROSTONE ISOPROPYL ESTER;

ALLERGY; AQUEOUS HUMOR OUTFLOW; BLOOD EYE BARRIER; BLOOD RETINA BARRIER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA EROSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SYNTHESIS; HEADACHE; HERPES SIMPLEX KERATITIS; HUMAN; HYPEREMIA; INTRAOCULAR PRESSURE; KERATOPATHY; MONOTHERAPY; OPEN ANGLE GLAUCOMA; PAIN; PATIENT COMPLIANCE; PIGMENTATION; PRESERVATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RETINA MACULA CYSTOID EDEMA; REVIEW; SCLERA; SYSTEMIC DISEASE; UVEA; UVEITIS; VISION;

ADRENERGIC BETA-ANTAGONISTS; CARBONIC ANHYDRASE INHIBITORS; CHOLINERGIC AGONISTS; DRUG THERAPY, COMBINATION; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; PROSTAGLANDINS; PROSTAGLANDINS F, SYNTHETIC;

EID: 0035070571     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.4.679     Document Type: Review

References (137)

1. Number of people with glaucoma worldwide
2. 2α
3. 2α on aqueous humor dynamics in cynomolgus monkeys
4. 2α increases uveoscleral outflow in the cynomolgus monkey Exp
5. 2α-1-isopropylester in the cynomolgus monkey
6. 2α on trabecular outflow facility in cynomolgus monkeys
7. A mechanism for reducing intraocular pressure in normal volunteers using UF-021, a prostaglandin-related compound
8. 2α analog, on aqueous humor dynamics in human eyes
9. 2α analogue
10. Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits
11. International union of pharmacology classification of prostanoid receptors; properties, distribution and structure of the receptors and their subtypes
12. Irin, a smooth-muscle contracting substance present in rabbit iris
13. Properties of irin, a physiological constituent of the rabbit's iris
14. 1 and aqueous humor dynamics
15. Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits
16. 2α on aqueous humor dynamics of rabbit, cat and monkey
17. 3 lower intraocular pressure
18. Marked differential effects of prostanoid metabolites on rabbit intraocular pressure
19. 2α
20. 2α on cat and rhesus monkey eyes
21. 2α or epinephrine on cynomolgus monkey eyes. II. Slit-lamp biomicroscopy, aqueous humor analysis and fluorescein angiography
22. 2α isopropyl ester versus Iloprost phenacyl ester in rabbit and beagle eyes
23. 2 and their esters in glaucomatous monkey eyes
24. 2α isopropylester on intraocular pressure in normotensive and glaucomatous canine eyes
25. 2α in the human eye
26. 2α-1-isopropyl ester
27. 2α esters across cornea in vitro
28. 2α
29. 2α-isopropylester eye drops. Effects in normal human eyes
30. 2α esters. A doublemasked cross-over study on normotensive eyes
31. Phenyl substituted prostaglandin analogs for glaucoma treatment
32. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol
33. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States
34. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension
35. The bioavailability of Xalatan® in the human eye
36. Prostaglandin derivates as ocular hypotensive agents
37. Effect of latanoprost on regional blood flow and capillary permeability in the monkey eye
38. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment
39. A comparative study of the effects of timolol and latanoprost on blood flow velocity on the retrobulbar vessels
40. Effects of 0.005% latanoprost on optic nerve head and peripapillary retinal blood flow
41. 2α-isopropyl ester analogues for glaucoma treatment
42. 2α analogue. Effect on intraocular pressure in patients with ocular hypertension
43. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study
44. Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma
45. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers
46. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose
47. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol
48. Effects on intraocular pressure and aqueous flow of various dose regimens of latanoprost in human eyes
49. Latanoprost twice daily is less effective than once daily. Indication of receptor subsensitivity?
50. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol
51. Effects of timolol, epinephrine and acetazolamide on aqueous flow during sleep
52. 2α analogue, after topical application in normal and ocular hypertensive human eyes
53. 2α
54. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro
55. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells
56. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections
57. Effects of prostaglandins on uveoscleral outflow
58. Topical prostaglandin F2alpha treatment reduces collagen types I, III and IV in the monkey uveoscleral outflow pathway
59. 2α effects on isolated rhesus monkey ciliary muscle
60. Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension
61. 2α analogue (PhXA41). An in-hospital, placebo-controlled study
62. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients
63. Latanoprost. Two years' experience of its use in the United Kingdom
64. Latanoprost: Experience of 2-year treatment in Scandinavia
65. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol
66. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma
67. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: A 3 month, randomised study
68. Effect of timolol, latanoprost and dorzolamide on circadian IOP in glaucoma or ocular hypertension
69. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with α adrenergic antagonists
70. Effects on latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability
71. 2α-isopropylester to timolol in patients with open angle glaucoma. A randomized, masked, placebo-controlled study
72. 2α-1-isopropyl ester to timolol in glaucoma patients
73. 2α analogue and timolol in patients with elevated intraocular pressure
74. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma
75. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: A randomized, observer-masked multicenter study in patients with open-angle glaucoma
76. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. A 6-month, randomized, multicenter study
77. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension
78. 2α/pilocarpine interactions on IOP and accomodation in monkeys
79. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure
80. Latanoprost and physostigmine have mostly additive ocular hypotensive effects in human eyes
81. Physostigmine increases aqueous humour production in human eyes
82. Early effects of epinephrine on aqueous humor dynamics in vervet monkeys (Cercopithecus ethiops)
83. Immediate effect of epinephrine on aqueous formation in the normal human eye as measured by fluorophotometry
84. Inhibition of the epinephrine-induced reduction of intraocular pressure by systemic indomethacin in humans
85. Effects of brimonidine on aqueous humor dynamics in human eyes
86. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients
87. The additive intra-ocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents
88. Fluorophotometry and the rate of aqueous flow in man. I. Instrumentation and normal values
89. Additive ocular hypotensive effect of latanoprost and acetazolamide
90. Combined effect of dorzolamide and latanoprost on the rate of aqueous humor flow
91. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure
92. Effect of latanoprost on intraocular pressure in patients with glaucoma on maximal tolerated medical therapy
93. Latanoprost for uncontrolled glaucoma in a compassionate case protocol
94. The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose or no pilocarpine therapy
95. Flow of aqueous humor in humans
96. 2α
97. The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma
98. Latanoprost and respiratory function in asthmatic patients. Randomized, double-masked, placebo-controlled crossover evaluation
99. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients
100. A Comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study
101. Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension
102. Corneal toxicity associated with latanoprost
103. Latanoprost and herpes simplex keratitis
104. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit
105. 2 receptor subtype
106. 2α analogue
107. Adverse side effects associated with latanoprost
108. Latanoprost and cystoid macular edema: Is there a causal relation?
109. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias
110. Cystoid macular edema and anterior uveitis associated with latanoprost use
111. Latanoprost 0.005% and anterior segment uveitis
112. Prostaglandin-induced increase of iridial pigmentation
113. Prostaglandin-induced iridial pigmentation in primates
114. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color
115. Evidence of early change in iris color with latanoprost use
116. Latanoprost-induced iris color darkening: A case report with long term follow-up
117. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost
118. Latanoprost and hyperpigmentation of eyelashes
119. Pharmacological characterization of prostaglandin-related ocular hypotensive agents
120. The intraocular pressure lowering effects of UF-021, a novel prostaglandin related compound in animals
121. Ocular effects of topical instillation of UF-021 ophthalmic solution in healthy volunteers
122. Effects of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes
123. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension
124. Clinical evaluation of UF-021 (Rescula®; Isopropyl unoprostone)
125. The effects of unoprostone isopropyl 0.12% and timolol maleate 0.5% on diurnal intraocular pressure
126. 2α metabolite, 0.12% unoprostone, in subjects with chronic open-angle glaucoma or ocular hypertension
127. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes
128. Substituting latanoprost (Xalatan) for isopropyl unoprostone (Rescula) in monotherapy and combination therapy
129. The ocular hypotensive effect of concomitant use of isopropyl unoprostone (Rescula®) and timolol
130. The additive effect of unoprostone ophthalmic solution for refractory glaucoma
131. Cell injury effect of isopropyl unoprostone, an antiglaucoma agent, on cultured human conjunctival cells
132. Effect of UF-021 (Rescula registered), a prostaglandin-related compound, on intraocular pressure and anterior chamber flare counts
133. Changes in ocular surface caused by antiglaucomatous eyedrops: Prospective, randomised study for the comparison of 0.5% timolol vs. 0.12% unoprostone
134. Iris-color change developed after topical isopropyl unoprostone treatment
135. Hypertrichosis caused by topical unoprostone
136. Travoprost. Antiglaucoma prostaglandin FP agonist